Targeted treatments have emerged as a safer and more effective option for eczema patients, but high costs remain a barrier.

With one in five children and one in 12 adults suffering from eczema, it’s a surprise that there’s not much to alleviate the miserable itching and dryness. Sufferers have complained that their ...

Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest bar of complete skin clearance (EASI 100 or IGA 0) and 87% achieved almost-clear skin (EASI 90) at three years with ...

Hollie's parents say a drug trial for eczema at Sheffield Children's Hospital gave her her life back.

TARRYTOWN, N.Y. and PARIS, June 28, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency will update the Dupixent® ...

In the U.S., 31.6 million people have at least one form of eczema. This skin condition affects all races, ethnicities, genders, and ages. But eczema can be slightly less or more common in specific ...

Eczema is a skin condition marked by dry, itchy, and inflamed skin. After childbirth, eczema may flare up due to the demands of child care and hormone changes in the body. During pregnancy and after ...

EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity. 2,3,4 The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type ...